Biotest is a specialist in innovative hematology, clinical immunology and intensive care medicine. Biotest develops, produces and sells plasma proteins and biotherapeutic drugs. The value chain includes pre-clinical and clinical development through to global marketing. Biotest produces immunoglobulins, coagulation factors and albumins on the basis of human blood plasma, which are used in diseases of the immune system or the blood-forming systems. Biotest employs more than 1,900 people worldwide.

The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and ultra-pure drugs in one of the most modern facilities in Europe. They are used in the therapy of life-threatening diseases such as blood clotting disorders (haemophilia), severe infections or disorders of the immune system.